The estimated Net Worth of Greef Roderick De is at least $19.7 Milion dollars as of 8 March 2024. Mr. De owns over 7,249 units of Biolife Solutions Inc stock worth over $10,710,394 and over the last 21 years he sold BLFS stock worth over $7,818,696. In addition, he makes $1,155,550 as Chief Financial Officer, Chief Operating Officer, Secretary a IR Contact Officer at Biolife Solutions Inc.
Roderick has made over 60 trades of the Biolife Solutions Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 7,249 units of BLFS stock worth $120,333 on 8 March 2024.
The largest trade he's ever made was buying 275,911 units of Biolife Solutions Inc stock on 19 February 2017 worth over $30,350. On average, Roderick trades about 15,343 units every 46 days since 2003. As of 8 March 2024 he still owns at least 461,854 units of Biolife Solutions Inc stock.
You can see the complete history of Mr. De stock trades at the bottom of the page.
Roderick de Greef serves as Chief Financial Officer, Chief Operating Officer, Secretary, IR Contact Officer of the Company. He has been Chief Financial Officer since May 2016. In December 2019, Mr. de Greef was additionally appointed Chief Operating Officer. He was appointed interim Chief Financial Officer and interim Secretary in March 2016. Previously, Mr. de Greef served as a director of the Company from June 2000 through November 2013, and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Since February 2019, Mr. de Greef has served as a director, chairman of the Audit Committee of the board of directors of Indonesia Energy Corporation Limited, an oil and gas exploration and production company. Mr. de Greef served Pareteum Corporation., a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of NASDAQ listed Cardiac Science, Inc., which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche’s Fast 500 listing. Mr. de Greef received his MBA degree from the University of Oregon, and a B.A in Economics and International Relations from San Francisco State University.
As the Chief Financial Officer, Chief Operating Officer, Secretary a IR Contact Officer of Biolife Solutions Inc, the total compensation of Roderick Greef at Biolife Solutions Inc is $1,155,550. There are 2 executives at Biolife Solutions Inc getting paid more, with Michael Rice having the highest compensation of $2,241,770.
Roderick Greef is 59, he's been the Chief Financial Officer, Chief Operating Officer, Secretary a IR Contact Officer of Biolife Solutions Inc since 2019. There are 4 older and 12 younger executives at Biolife Solutions Inc. The oldest executive at Biolife Solutions Inc is Thomas Girschweiler, 61, who is the Director.
Greef's mailing address filed with the SEC is 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WA, 98021.
Over the last 21 years, insiders at Biolife Solutions Inc have traded over $156,215,880 worth of Biolife Solutions Inc stock and bought 12,236,637 units worth $91,960,074 . The most active insiders traders include Partners Master Fund, L.P.C..., Thomas Girschweiler a Walter Villiger. On average, Biolife Solutions Inc executives and independent directors trade stock every 13 days with the average trade being worth of $1,018,157. The most recent stock trade was executed by Sarah Aebersold on 1 July 2024, trading 3,000 units of BLFS stock currently worth $63,090.
bothell, wa-based biolife solutions, inc. (nasdaq: blfs), is a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers.
Biolife Solutions Inc executives and other stock owners filed with the SEC include: